Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho Exchanges Opinions with NPhA on Generics, Distribution
December 25, 2006
- Financial Support to Be Provided to Fewer Patients with Ulcerative Colitis, Parkinson's Disease
December 25, 2006
- JGPMA Proposes "Drug Benefit Standard Price System"
December 25, 2006
- MEDICAL DEVICE NEWS IN BRIEF
December 18, 2006
- NEW PRODUCTS
December 18, 2006
- NEW PRODUCTS
December 18, 2006
- REGULATORY NEWS IN BRIEF
December 18, 2006
- NIBIO Partnership Forum
December 18, 2006
- Tokai Univ. Symposium on Transfer of Technology
December 18, 2006
- Prime Minister Expresses High Hopes of Pharmaceutical Industry
December 18, 2006
- REGULATORY NEWS IN BRIEF
December 18, 2006
- Japanese Gov't Asks for Regular Meetings Between Japanese Companies and US FDA
December 18, 2006
- Institute Issues Proposals to Promote Regenerative Medicine
December 18, 2006
- Nichi-Iko Providing Third-party Data on Its Products
December 18, 2006
- US-Japan Gap in Approval Time Grew in 2005: OPIR
December 18, 2006
- ON THE MOVE
December 18, 2006
- Case Report on Problems with Generics Presented
December 18, 2006
- BUSINESS NEWS IN BRIEF
December 18, 2006
- Synix to Launch Improved Cancer Treatment Database
December 18, 2006
- ADVATE to Reach Japanese Hemophiliacs: Baxter
December 18, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…